REG - Synairgen plc - Grant of Options

SynairgenAnnouncement

15/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231115:nRSO4597Ta&default-theme=true

RNS Number : 4597T  Synairgen plc  15 November 2023

 

Synairgen plc

('Synairgen' or the 'Company')

Grant of Options

 

Southampton, UK - 15 November 2023: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001, an investigational formulation for inhalation
containing the broad-spectrum antiviral protein interferon beta, announces
that on 14 November 2023 the Board of Synairgen granted options ('Options')
over 1,900,000 ordinary shares of one pence each in the capital of the Company
('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The
Options represent in aggregate 0.94 per cent. of the Company's issued share
capital.

Following this grant, Synairgen has 18,940,446 options in issue, representing
9.41 per cent. of the Company's issued share capital.

Certain Options were issued to the recently recruited Chief Financial Officer
and Chief Medical Officer respectively, the former a Director of the Company;
the later a Persons Discharging Managerial Responsibilities ('PDMR'):

                   Options issued      14 Nov 2023       Total options  Ordinary shares  Total interest  Percentage holding of fully diluted share capital
 Directors
 Joseph Colliver   750,000                               750,000        -                750,000         0.34%
 PDMRs
 Marcin Mankowski  750,000                               750,000        -                750,000         0.34%

 

 

The Options are issued under the Company's Long Term Incentive Plan and are
exercisable up to 13 November 2033, subject to the achievement of appropriate
performance criteria which match the criteria for the 2022 award as set out on
page 23 of the 2022 annual report.

The information contained within this announcement is deemed to constitute
inside information as stipulated under the retained EU law version of the
Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK
law by virtue of the European Union (Withdrawal) Act 2018.

 

For further enquiries, please contact:

Synairgen plc

Media@synairgen.com (mailto:Media@synairgen.com)

Tel: + 44 (0) 23 8051 2800

 

Cavendish Capital Markets Limited (NOMAD and Joint Broker)

Geoff Nash, Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

 

Deutsche Numis (Joint Broker)

Freddie Barnfield, Duncan Monteith, Euan Brown

Tel: + 44 (0) 20 7260 1000

 

ICR Consilium (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

cscsynairgen@consilium-comms.com (mailto:cscsynairgen@consilium-comms.com)

Tel: +44 (0) 20 3709 5700

 

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery and the
development of SNG001 (inhaled interferon beta) as potentially the first
host-targeted, broad-spectrum antiviral treatment delivered directly into the
lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung
infections and there are currently no approved antiviral therapies for the
majority of these patients. Synairgen is developing SNG001 to address this
need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com

 

 1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person
     closely associated with them ('PCA')
 a)  Name                                     Joseph Colliver
 2.  Reason for notification
 a)  Position / status                        Chief Financial Officer
 b)  Initial notification / amendment         Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     Synairgen plc
 b)  LEI                                      213800IMMTOPPDF8HD24
 4.  Details of the transaction(s):
 a)  Description of the financial instrument  Options over ordinary shares of 1p each

     Identification code

                                              GB00B0381Z20
 b)  Nature of the transaction                Award of Options under the Company's share plans
 c)  Price(s) and volume(s)                   750,000 Options awarded

                                              Exercise price of one pence
 d)  Aggregated information                   n/a

     Aggregated volume Price
 e)  Date of the transaction                  14 November 2023
 f)  Place of the transaction                 Outside a trading venue

 

 

 1.  Details of Persons Discharging Managerial Responsibilities ('PDMR') / person
     closely associated with them ('PCA')
 a)  Name                                     Dr Marcin Mankowski
 2.  Reason for notification
 a)  Position / status                        Chief Medical Officer
 b)  Initial notification / amendment         Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     Synairgen plc
 b)  LEI                                      213800IMMTOPPDF8HD24
 4.  Details of the transaction(s):
 a)  Description of the financial instrument  Options over ordinary shares of 1p each

     Identification code

                                              GB00B0381Z20
 b)  Nature of the transaction                Award of Options under the Company's share plans
 c)  Price(s) and volume(s)                   750,000 Options awarded

                                              Exercise price of one pence
 d)  Aggregated information                   n/a

     Aggregated volume Price
 e)  Date of the transaction                  14 November 2023
 f)  Place of the transaction                 Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAEFLFEADFAA